Preclinical evaluation of a modified vaccinia virus Ankara (MVA)-based vaccine against influenza A/H5N1 viruses

Vaccine

Volumn 27, Issue 45, 2009, Pages 6296-6299

  Kreijtz, J H C M ^a   Suezer, Y ^b   de Mutsert, G ^a   van den Brand, J M A ^a   van Amerongen, G ^a   Schnierle, B S ^b   Kuiken, T ^a   Fouchier, R A M ^a   Lower J ^b   Osterhaus, A D M E ^a   Sutter, G ^b   Rimmelzwaan, G F ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b PAUL EHRLICH INSTITUT   (Germany)

Author keywords

H5N1; Influenza; Mice; MVA; Non human primate; Vaccine

Indexed keywords

MODIFIED VACCINIA VIRUS ANKARA 5T4 VACCINE; RECOMBINANT VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CLADISTICS; CONTROLLED STUDY; CROSS REACTION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; EVALUATION; FEMALE; GENE EXPRESSION; HA GENE; HUMAN; IMMUNIZATION; INDONESIA; INFLUENZA VIRUS A H5N1; LETHALITY; LOWER RESPIRATORY TRACT INFECTION; MACACA; MOUSE; NECROTIZING BRONCHOINTERSTITIAL PNEUMONIA; NONHUMAN; PANDEMIC; PNEUMONIA; PRIORITY JOURNAL; UPPER RESPIRATORY TRACT INFECTION; VIET NAM; VIRUS GENE; VIRUS IMMUNITY; VIRUS INHIBITION; VIRUS LOAD; VIRUS STRAIN; VIRUS TITRATION;

ANIMALS; ANTIBODIES, VIRAL; FEMALE; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; MACACA FASCICULARIS; MICE; MICE, INBRED C57BL; ORTHOMYXOVIRIDAE INFECTIONS; VACCINIA VIRUS;

EID: 70349974553     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.03.020     Document Type: Article

References (30)

1. WHO. Cumulative Number of Confirmed Human Cases of Avian Influenza A/(H5N1) Reported to WHO http://www.who.int/csr/disease/avian_influenza/country/cases_table_2008_09_10/en/index.html; 2008 [accessed November 11, 2008].
2. WHO. Antigenic and genetic characteristics of H5N1 viruses and candidate H5N1 vaccine viruses developed for potential use as human vaccines, http://www.who.int/csr/disease/avian_influenza/guidelines/200809_H5VaccineVirusUpdate.pdf; 2008.
3. Kreijtz J.H.C.M., Osterhaus A.D.M.E., and Rimmelzwaan G.F. Vaccination strategies and vaccine formulations for epidemic and pandemic influenza control. Hum Vaccine 5 May (5) (2009)
4. Sutter G., and Staib C. Vaccinia vectors as candidate vaccines: the development of modified vaccinia virus Ankara for antigen delivery. Curr Drug Targets Infect Disord 3 September (3) (2003) 263-271
5. Mayr A., Stickl H., Muller H.K., Danner K., and Singer H. Der Pockenimpfstamm MVA: Marker, genetische Struktur, Erfahrungen mit der parenteralen Schutzimpfung und Verhalten im abwehrgeschwachten Organismus. Zentralbl Bakteriol [B] 167 December (5-6) (1978) 375-390
6. Stittelaar K.J., Kuiken T., de Swart R.L., van Amerongen G., Vos H.W., Niesters H.G., et al. Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques. Vaccine 19 June (27) (2001) 3700-3709
7. Stickl H., and Hochstein-Mintzel V. [Intracutaneous smallpox vaccination with a weak pathogenic vaccinia virus ("MVA virus")] Die intrakutane Pockenimpfung mit einem schwach virulenten Vakzinia-Virus ("MVA-Virus"). Munch Med Wochenschr 113 August (35) (1971) 1149-1153
8. Drexler I., Staib C., and Sutter G. Modified vaccinia virus Ankara as antigen delivery system: how can we best use its potential?. Curr Opin Biotechnol 15 December (6) (2004) 506-512
9. Sutter G., Wyatt L.S., Foley P.L., Bennink J.R., and Moss B. A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus. Vaccine 12 August (11) (1994) 1032-1040
10. Garcia-Hernandez E., Gonzalez-Sanchez J.L., Andrade-Manzano A., Contreras M.L., Padilla S., Guzman C.C., et al. Regression of papilloma high-grade lesions (CIN 2 and CIN 3) is stimulated by therapeutic vaccination with MVA E2 recombinant vaccine. Cancer Gene Ther 13 June (6) (2006) 592-597
11. Harrop R., Connolly N., Redchenko I., Valle J., Saunders M., Ryan M.G., et al. Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a phase I/II trial. Clin Cancer Res 12 June (11 Pt 1) (2006) 3416-3424
12. Harrop R., Drury N., Shingler W., Chikoti P., Redchenko I., Carroll M.W., et al. Vaccination of colorectal cancer patients with modified vaccinia ankara encoding the tumor antigen 5T4 (TroVax) given alongside chemotherapy induces potent immune responses. Clin Cancer Res 13 August (15 Pt 1) (2007) 4487-4494
13. Cosma A., Nagaraj R., Buhler S., Hinkula J., Busch D.H., Sutter G., et al. Therapeutic vaccination with MVA-HIV-1 nef elicits Nef-specific T-helper cell responses in chronically HIV-1 infected individuals. Vaccine 22 December (1) (2003) 21-29
14. McShane H., Pathan A.A., Sander C.R., Keating S.M., Gilbert S.C., Huygen K., et al. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat Med 10 November (11) (2004) 1240-1244
15. Moss B., Carroll M.W., Wyatt L.S., Bennink J.R., Hirsch V.M., Goldstein S., et al. Host range restricted, non-replicating vaccinia virus vectors as vaccine candidates. Adv Exp Med Biol 397 (1996) 7-13
16. Ramirez J.C., Gherardi M.M., Rodriguez D., and Esteban M. Attenuated modified vaccinia virus Ankara can be used as an immunizing agent under conditions of preexisting immunity to the vector. J Virol 74 August (16) (2000) 7651-7655
17. Wang Z., La Rosa C., Maas R., Ly H., Brewer J., Mekhoubad S., et al. Recombinant modified vaccinia virus Ankara expressing a soluble form of glycoprotein B causes durable immunity and neutralizing antibodies against multiple strains of human cytomegalovirus. J Virol 78 April (8) (2004) 3965-3976
18. Moss B. Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc Natl Acad Sci USA 93 October (21) (1996) 11341-11348
19. Kreijtz J.H., Suezer Y., van Amerongen G., de Mutsert G., Schnierle B.S., Wood J.M., et al. Recombinant modified vaccinia virus Ankara-based vaccine induces protective immunity in mice against infection with influenza virus H5N1. J Infect Dis 195 June (11) (2007) 1598-1606
20. Kreijtz J.H., Suezer Y., de Mutsert G., van den Brand J.M., van Amerongen G., Schnierle B.S., et al. Recombinant modified vaccinia virus Ankara expressing the hemagglutinin gene confers protection against homologous and heterologous H5N1 influenza virus infections in macaques. J Infect Dis 199 February (3) (2009) 405-413
21. Palmer D., Dowle W., Coleman M., and Schild G. Haemagglutination inhibition test. Advanced laboratory techniques for influenza diagnosis. Procedural guide (1975), US Department of Health, Atlanta p. 25-62
22. Frank A.L., Puck J., Hughes B.J., and Cate T.R. Microneutralization test for influenza A and B and parainfluenza 1 and 2 viruses that uses continuous cell lines and fresh serum enhancement. J Clin Microbiol 12 September (3) (1980) 426-432
23. Yewdell J.W., Bennink J.R., Smith G.L., and Moss B. Influenza A virus nucleoprotein is a major target antigen for cross-reactive anti-influenza A virus cytotoxic T lymphocytes. Proc Natl Acad Sci USA 82 March (6) (1985) 1785-1789
24. McMichael A.J., Michie C.A., Gotch F.M., Smith G.L., and Moss B. Recognition of influenza A virus nucleoprotein by human cytotoxic T lymphocytes. J Gen Virol 67 April (Pt 4) (1986) 719-726
25. Kreijtz J.H., de Mutsert G., van Baalen C.A., Fouchier R.A., Osterhaus A.D., and Rimmelzwaan G.F. Cross-recognition of avian H5N1 influenza virus by human cytotoxic T-lymphocyte populations directed to human influenza A virus. J Virol 82 June (11) (2008) 5161-5166
26. Kreijtz J.H., Bodewes R., van Amerongen G., Kuiken T., Fouchier R.A., Osterhaus A.D., et al. Primary influenza A virus infection induces cross-protective immunity against a lethal infection with a heterosubtypic virus strain in mice. Vaccine 25 January (4) (2007) 612-620
27. Lee L.Y., Ha D.L., Simmons C., de Jong M.D., Chau N.V., Schumacher R., et al. Memory T cells established by seasonal human influenza A infection cross-react with avian influenza A (H5N1) in healthy individuals. J Clin Invest September (2008)
28. Epstein S.L. Prior H1N1 influenza infection and susceptibility of Cleveland Family Study participants during the H2N2 pandemic of 1957: an experiment of nature. J Infect Dis 193 January (1) (2006) 49-53
29. Jameson J., Cruz J., Terajima M., and Ennis F.A. Human CD8+ and CD4+ T lymphocyte memory to influenza A viruses of swine and avian species. J Immunol 162 June (12) (1999) 7578-7583
30. McMichael A.J., Gotch F.M., Noble G.R., and Beare P.A. Cytotoxic T-cell immunity to influenza. N Engl J Med 309 July (1) (1983) 13-17